TISIDB

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Cell projection, cilium Note=STK36 promotes translocation to the nucleus. In keratinocytes, it is sequestered in the cytoplasm by SUFU. In the absence of SUFU, it translocates to the nucleus. ; SUBCELLULAR LOCATION: Isoform 1: Nucleus ; SUBCELLULAR LOCATION: Isoform 2: Nucleus
Domain	-
Function	Functions as transcription regulator in the hedgehog (Hh) pathway (PubMed:18455992, PubMed:26565916). Functions as transcriptional activator (PubMed:9557682, PubMed:19878745, PubMed:24311597). May also function as transcriptional repressor (By similarity). Requires STK36 for full transcriptional activator activity. Required for normal embryonic development (PubMed:15994174, PubMed:20685856). ; FUNCTION: Isoform 1, isoform 2, isoform 3 and isoform 4: Act as transcriptional activators in T-cell leukemia virus type 1 (HTLV-1)-infected cells in a Tax-dependent manner. Bind to the DNA sequence 5'-GAACCACCCA-3' which is part of the Tax-responsive element (TRE-2S) regulatory element that augments the Tax-dependent enhancer of HTLV-1 (PubMed:9557682). Are involved in the smoothened (SHH) signaling pathway (PubMed:18455992). ; FUNCTION: Isoform 5: Acts as a transcriptional repressor.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001655 urogenital system development GO:0001701 in utero embryonic development GO:0001708 cell fate specification GO:0001763 morphogenesis of a branching structure GO:0001822 kidney development GO:0002062 chondrocyte differentiation GO:0002076 osteoblast development GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0003002 regionalization GO:0006260 DNA replication GO:0006275 regulation of DNA replication GO:0007159 leukocyte cell-cell adhesion GO:0007224 smoothened signaling pathway GO:0007389 pattern specification process GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007418 ventral midline development GO:0007423 sensory organ development GO:0007442 hindgut morphogenesis GO:0007507 heart development GO:0008589 regulation of smoothened signaling pathway GO:0009612 response to mechanical stimulus GO:0009952 anterior/posterior pattern specification GO:0009953 dorsal/ventral pattern formation GO:0009954 proximal/distal pattern formation GO:0010720 positive regulation of cell development GO:0016331 morphogenesis of embryonic epithelium GO:0021508 floor plate formation GO:0021510 spinal cord development GO:0021511 spinal cord patterning GO:0021513 spinal cord dorsal/ventral patterning GO:0021514 ventral spinal cord interneuron differentiation GO:0021515 cell differentiation in spinal cord GO:0021517 ventral spinal cord development GO:0021520 spinal cord motor neuron cell fate specification GO:0021521 ventral spinal cord interneuron specification GO:0021522 spinal cord motor neuron differentiation GO:0021532 neural tube patterning GO:0021536 diencephalon development GO:0021549 cerebellum development GO:0021575 hindbrain morphogenesis GO:0021587 cerebellum morphogenesis GO:0021695 cerebellar cortex development GO:0021696 cerebellar cortex morphogenesis GO:0021775 smoothened signaling pathway involved in ventral spinal cord interneuron specification GO:0021776 smoothened signaling pathway involved in spinal cord motor neuron cell fate specification GO:0021904 dorsal/ventral neural tube patterning GO:0021910 smoothened signaling pathway involved in ventral spinal cord patterning GO:0021915 neural tube development GO:0021936 regulation of cerebellar granule cell precursor proliferation GO:0021937 cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of granule cell precursor cell proliferation GO:0021938 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021940 positive regulation of cerebellar granule cell precursor proliferation GO:0021952 central nervous system projection neuron axonogenesis GO:0021953 central nervous system neuron differentiation GO:0021954 central nervous system neuron development GO:0021955 central nervous system neuron axonogenesis GO:0021965 spinal cord ventral commissure morphogenesis GO:0021983 pituitary gland development GO:0022037 metencephalon development GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0022612 gland morphogenesis GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0030323 respiratory tube development GO:0030324 lung development GO:0030326 embryonic limb morphogenesis GO:0030850 prostate gland development GO:0030879 mammary gland development GO:0030900 forebrain development GO:0030902 hindbrain development GO:0030903 notochord development GO:0032330 regulation of chondrocyte differentiation GO:0032331 negative regulation of chondrocyte differentiation GO:0033077 T cell differentiation in thymus GO:0033081 regulation of T cell differentiation in thymus GO:0033089 positive regulation of T cell differentiation in thymus GO:0033504 floor plate development GO:0033505 floor plate morphogenesis GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0035239 tube morphogenesis GO:0035270 endocrine system development GO:0042110 T cell activation GO:0042471 ear morphogenesis GO:0042472 inner ear morphogenesis GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0042733 embryonic digit morphogenesis GO:0043583 ear development GO:0045165 cell fate commitment GO:0045580 regulation of T cell differentiation GO:0045582 positive regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045666 positive regulation of neuron differentiation GO:0045740 positive regulation of DNA replication GO:0045785 positive regulation of cell adhesion GO:0048546 digestive tract morphogenesis GO:0048562 embryonic organ morphogenesis GO:0048565 digestive tract development GO:0048566 embryonic digestive tract development GO:0048568 embryonic organ development GO:0048570 notochord morphogenesis GO:0048608 reproductive structure development GO:0048645 animal organ formation GO:0048663 neuron fate commitment GO:0048665 neuron fate specification GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048732 gland development GO:0048736 appendage development GO:0048754 branching morphogenesis of an epithelial tube GO:0048839 inner ear development GO:0050769 positive regulation of neurogenesis GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051216 cartilage development GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051962 positive regulation of nervous system development GO:0055123 digestive system development GO:0060032 notochord regression GO:0060033 anatomical structure regression GO:0060173 limb development GO:0060443 mammary gland morphogenesis GO:0060512 prostate gland morphogenesis GO:0060513 prostatic bud formation GO:0060541 respiratory system development GO:0060562 epithelial tube morphogenesis GO:0060571 morphogenesis of an epithelial fold GO:0060572 morphogenesis of an epithelial bud GO:0060573 cell fate specification involved in pattern specification GO:0060579 ventral spinal cord interneuron fate commitment GO:0060581 cell fate commitment involved in pattern specification GO:0060601 lateral sprouting from an epithelium GO:0060603 mammary gland duct morphogenesis GO:0060740 prostate gland epithelium morphogenesis GO:0060831 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0061035 regulation of cartilage development GO:0061037 negative regulation of cartilage development GO:0061138 morphogenesis of a branching epithelium GO:0061180 mammary gland epithelium development GO:0061448 connective tissue development GO:0061458 reproductive system development GO:0061525 hindgut development GO:0061564 axon development GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071407 cellular response to organic cyclic compound GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0072001 renal system development GO:0090102 cochlea development GO:0090103 cochlea morphogenesis GO:0090596 sensory organ morphogenesis GO:0097485 neuron projection guidance GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000177 regulation of neural precursor cell proliferation GO:2000179 positive regulation of neural precursor cell proliferation GO:2000398 regulation of thymocyte aggregation GO:2000400 positive regulation of thymocyte aggregation
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding
Cellular Component	GO:0005929 cilium GO:0005930 axoneme GO:0016604 nuclear body GO:0016607 nuclear speck GO:0031512 motile primary cilium GO:0044441 ciliary part GO:0072372 primary cilium GO:0097014 ciliary plasm GO:0097542 ciliary tip GO:0097546 ciliary base

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04340 Hedgehog signaling pathway hsa04390 Hippo signaling pathway
Reactome	R-HSA-5610783: Degradation of GLI2 by the proteasome R-HSA-5635851: GLI proteins bind promoters of Hh responsive genes to promote transcription R-HSA-5610787: Hedgehog 'off' state R-HSA-5632684: Hedgehog 'on' state R-HSA-162582: Signal Transduction R-HSA-5358351: Signaling by Hedgehog

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GLI2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GLI2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GLI2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.394	0.0889
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.422	0.336
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.377	0.291
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.097	0.815
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.126	0.947
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.059	0.98
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.898	0.0841
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.696	0.377
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.044	0.227
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.044	0.938
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.79	0.282
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.618	0.00302

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GLI2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	21.4	0	21.4	0.081
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	30	0	30	0.528
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	18.5	6.8	11.7	0.128
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	18.5	6.8	11.7	0.132
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	17.6	-17.6	0.0806
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	27.3	-27.3	0.0815
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	14.3	-8.1	0.586
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GLI2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GLI2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GLI2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GLI2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GLI2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GLI2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GLI2
Name	GLI family zinc finger 2
Aliases	THP2; HPE9; THP1; tax-responsive element-2 holding protein; tax helper protein 1; tax helper protein 2; GLI- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GLI2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GLI2